Frost & Sullivan Independent Equity Research

BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.


Company: BioLineRx        

Sector: Pharmaceuticals

Report type: Quarterly Update

For all past reports click here

Published on: September 6th 2017